Due to failure of many tau and Aβ based therapeutic strategies (Extance, 2010; Rinne et al., 2010), more drug development researches are now being shifted toward multitarget-directed ligands approaches like disease-modifying therapies (DMTs) which temporarily slow the worsening of dementia symptoms of those patients with AD and other dementias (Paoletti et al., 2013; Henley and Wilkinson, 2016). The gene discussed is MAPT; the disease is Alzheimer disease.